References | Disease | Technology | MS mode | Feature | Biomarkers | Disease severity predicted by the biomarkers |
---|---|---|---|---|---|---|
Adduri, et al. [24] | ILD | LC–MS/MS | DDA | Diagnosis for IPF | SFTPB, ALDOA, HMGB1, CALML5, and TLN1 | Diagnostic/classification use |
Enomoto, et al. [25] | ILD | LC–MS/MS | DIA | Diagnosis for PPF | SFTPB | Unfavorable |
Tomoto, et al. [26] | ILD | LC–MS/MS | DIA | Estimation of IPF‑specific protein network | - | - |
Yoshimura, et al. [37] | BA | LC–MS/MS | DIA | Diagnosis for eosinophilic BA | Gal-10 | Unfavorable |
Koba, et al. [45] | COPD | LC–MS/MS | DDA | Diagnosis for COPD | Fibulin-3 | Unfavorable |
Jung, et al. [46] | COPD | EV array analysis |  | Diagnosis for acute exacerbation of COPD | CD45 and CD28 | Diagnostic/classification use |
Mao, et al. [60] | COVID-19 | LC–MS/MS | DIA | Characteristics and residual traces of recovered COVID-19 patients | Proteins associated with coagulation activity, inflammatory reaction, immune response, and low organ function | Diagnostic/classification use |
Krishnamachary, et al. [62] | COVID-19 | PEA | - | Diagnosis of severe patients | TF, CD163, and EN-RAGE | Unfavorable |
Fujita, et al. [61] | COVID-19 | LC–MS/MS | DDA | Predictive biomarkers of severe patients | COPB2 | Favorable |
Lam, et al. [49] | COVID-19 | LC–MS/MS | DDA | Proteomics change of different temporal stages of COVID-19 | C1r, C1s | Diagnostic/classification use |
Kawasaki, et al. [63] | COVID-19 | LC–MS/MS | DIA | Predictive biomarkers of refractory patients | MACROH2A1 | Unfavorable |
Mehaffy, et al. [70] | M. tuberculosis | MRM-MS | - | Identification of peptides associated with LTBI | glutamine synthetase (GlnA1) enzyme | Diagnostic/classification use |
Cheng, et al. [71] | Pediatric pneumonia | LC–MS/MS | DDA | Immune signatures of children with pneumonia | SERPINA1, ITIH4, IGLV6-57, HIST2H3A, HIST1H4, HIST1H2BL, COL1A1, ANXA2, COL2A1, ACAN, DSP, XP32, DSC1, HAPLN1, and DSG1 | Diagnostic/classification use |